Use of Nucleic Acid Tests To Reduce the Risk of Transmission of West Nile Virus From Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Correction

---
identifier: "/us/fr/2016-23514"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Use of Nucleic Acid Tests To Reduce the Risk of Transmission of West Nile Virus From Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2016-23514"
section_name: "Use of Nucleic Acid Tests To Reduce the Risk of Transmission of West Nile Virus From Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Correction"
positive_law: false
currency: "2016-09-29"
last_updated: "2016-09-29"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2016-23514"
document_type: "notice"
publication_date: "2016-09-29"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "81 FR 66967"
fr_volume: 81
docket_ids:
  - "Docket No. FDA-2013-D-1143"
fr_action: "Notice of availability; correction."
---


#  Use of Nucleic Acid Tests To Reduce the Risk of Transmission of West Nile Virus From Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice of availability; correction.

**SUMMARY:**

The Food and Drug Administration (FDA or Agency) is correcting a notice that appeared in the *Federal Register* of Tuesday, September 13, 2016 (81 FR 62910). The document announced the availability of a guidance for industry entitled “Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). The document was published with incorrect information of a comment period due date. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Jonathan McKnight, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.

**SUPPLEMENTARY INFORMATION:**

In the *Federal Register* of September 13, 2016, in FR Doc. 2016-21969, on page 62910, the following correction is made:

On page 62910, in the first column under the *DATES:* caption, the sentence is corrected to read, “Submit either electronic or written comments on Agency guidances at any time.”

Dated: September 23, 2016.

Leslie Kux,

Associate Commissioner for Policy.